UBS Group cut shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a strong-buy rating to an outperform rating in a research report report published on Thursday, January 4th, The Fly reports.

A number of other research firms have also recently weighed in on ALXN. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price target on the stock in a report on Tuesday, October 31st. BidaskClub upgraded shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, December 27th. Leerink Swann restated an outperform rating and issued a $182.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Credit Suisse Group reaffirmed a buy rating and issued a $166.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Stifel Nicolaus decreased their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating for the company in a research report on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $153.10.

Alexion Pharmaceuticals (ALXN) opened at $126.79 on Thursday. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34. The stock has a market cap of $28,616.54, a PE ratio of 56.60, a price-to-earnings-growth ratio of 1.07 and a beta of 1.18.

In other news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.35% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Twin Capital Management Inc. raised its holdings in Alexion Pharmaceuticals by 26.5% in the 4th quarter. Twin Capital Management Inc. now owns 38,786 shares of the biopharmaceutical company’s stock valued at $4,638,000 after buying an additional 8,136 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in Alexion Pharmaceuticals by 50.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 15,980 shares of the biopharmaceutical company’s stock valued at $1,908,000 after buying an additional 5,375 shares during the period. Lourd Capital LLC purchased a new stake in Alexion Pharmaceuticals in the 4th quarter valued at about $221,000. Harbour Capital Advisors LLC purchased a new stake in Alexion Pharmaceuticals in the 4th quarter valued at about $347,000. Finally, Peregrine Capital Management LLC raised its holdings in Alexion Pharmaceuticals by 29.7% in the 4th quarter. Peregrine Capital Management LLC now owns 126,320 shares of the biopharmaceutical company’s stock valued at $15,107,000 after buying an additional 28,900 shares during the period. Institutional investors and hedge funds own 94.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Marea Informative and is the property of of Marea Informative. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.mareainformativa.com/ubs-group-lowers-alexion-pharmaceuticals-alxn-to-outperform-updated-updated-updated/126306/.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.